Anthony Giovinazzo, MBA, C.Dir, A.C.C.

As Senior Transaction Advisor, Anthony assists Ferghana with respect to the origination, analysis and execution of transactions primarily involving Canadian therapeutic, Canadian diagnostic, and Canadian healthcare companies at all stages of their development. He has many decades of experience in either advising on matters involving, or acting as a senior executive and Board Member managing, Intellectual Property, drug development programs, and product commercialization (including licensing transactions) on an international basis.. Anthony has particular experience in the CNS field because he was co-inventor, CEO, and a Director of Cynapsus, a NASDAQ-listed company that successfully developed a thin-film apomorphine strip for the treatment of Parkinson’s Disease. Anthony sold Cynapsus to Dainippon Sumitomo Pharmaceutics for C$841M. He is currently a Director at Conavi Medical (hardware used in minimally-invasive cardiovascular procedures) and is also Chair at Xortx Therapeutics (a Phase III company finalizing development of oxy-purinol for kidney and gout disease).

Anthony has a substantial academic career where he has lectured at many institutions and conferences, as well as being the graduate of The Directors College/McMaster University (Chartered Director and Audit Committee Certified) and IMD in Geneva (MBA), Osgoode Hall Law School/York University (Canadian Law), and McMaster University (BA in Economics and Accounting).